Renal Denervation Market: Impact of Major Barriers Underestimated by Industry Experts, Says GlobalData Analyst
10/10/2013 8:30:19 AM
LONDON, UK (GlobalData), 10 October 2013 - Since its debut back in 2010, the renal denervation market has generated significant enthusiasm across the medical device industry, with predictions that the market would reach more than one billion dollars by 2020; but, the impact of major barriers, which will slow down this growth, was essentially underestimated, according to an analyst with research and consulting firm GlobalData.
Joseph Gregory, GlobalData's Analyst covering Surgical Devices, says that one of the most pressing barriers is reimbursements. Renal denervation has been approved in Europe since 2010, but has only seen full reimbursement in Germany and Austria as of 2013.
The analyst says: “The various European-run health insurance agencies are not entirely convinced of the long-term safety and efficacy of the procedure, due to the lack of available data from sophisticated clinical trials. Currently, procedures in these countries are either being funded out of pocket or by a portion of hospital budgets dedicated toward the use of novel technologies.”
Another significant hurdle for the renal denervation market is the establishment of a completely new referral pattern. Renal denervation is performed by cardiologists and radiologists. However, patients typically will see their primary care physician first, and once uncontrolled hypertension is diagnosed, they will be referred to a hypertension specialist or cardiologist who will then make a final referral for the procedure.
“Medical device companies which specialize in interventional cardiology products have strong, established relationships with cardiologists, but their network does not extensively breach this first line of referral from primary care physicians. Thus, the sales and marketing teams of renal denervation companies have the difficult job of developing this network from scratch,” Gregory says.
The current state of the clinical trial data will also constrain the market, according to Gregory. While company-sponsored studies have to date proven short-term safety and efficacy, there is still ambiguity with regards to device performance in the long term, as well as the degree of efficacy that can be achieved.
Gregory continues: “Further, looking at long-term procedure outcomes for renal denervation, there is very limited data available, as the longest follow-up to date is just three years, from Medtronic’s open-label, non-randomized Symplicity HTN-1 study.
“Overall, taking into consideration the full impact of these and numerous other market barriers, it is doubtful that renal denervation will prove to be the next blockbuster in the medical device industry,” the analyst concludes.
- Comment provided by Joseph Gregory, GlobalData's Analyst covering Surgical Devices.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 528 or at firstname.lastname@example.org.
Help employers find you! Check out all the jobs and post your resume.
comments powered by